Mitoxantrone: a review of its use in multiple sclerosis
LJ Scott, DP Figgitt - CNS drugs, 2004 - Springer
Mitoxantrone (Novantrone®), a synthetic anthracenedione derivative, is an antineoplastic,
immunomodulatory agent. Its presumed mechanism of action in patients with multiple …
immunomodulatory agent. Its presumed mechanism of action in patients with multiple …
Glatiramer acetate: a review of its use in relapsing-remitting multiple sclerosis
D Simpson, S Noble, C Perry - Cns Drugs, 2002 - Springer
Glatiramer acetate is a synthetic copolymer composed of a random mixture of four amino
acids that modifies the immune response that results in the CNS inflammation …
acids that modifies the immune response that results in the CNS inflammation …
A questionnaire to assess neurological impairment in multiple sclerosis
DS Goodin - Multiple Sclerosis Journal, 1998 - journals.sagepub.com
This study assessed the feasibility of using a self-report questionnaire to measure
neurological impairment in multiple sclerosis (MS). Thirty patients aged 21-67 years …
neurological impairment in multiple sclerosis (MS). Thirty patients aged 21-67 years …
Management of secondary-progressive multiple sclerosis
G Giovannoni - CNS drugs, 2004 - Springer
The majority of patients with relapse-onset multiple sclerosis (MS) will go on to develop
secondary-progressive MS (SPMS) disease, with approximately 50% developing SPMS …
secondary-progressive MS (SPMS) disease, with approximately 50% developing SPMS …
Cladribine: a review of its use in multiple sclerosis
HD Langtry, HM Lamb - BioDrugs, 1998 - Springer
Cladribine is a deaminase-resistant deoxyadenosine analogue that selectively reduces
lymphocyte counts. The drug is an effective therapy for selected haematological …
lymphocyte counts. The drug is an effective therapy for selected haematological …
Interferon-β-1a: a review of its pharmacological properties and therapeutic potential in multiple sclerosis
SM Holliday, P Benfield - BioDrugs, 1997 - Springer
The presumed but as yet unspecified autoimmune-mediated basis for the pathogenesis of
multiple sclerosis has led to attempts to modify the immune system of patients with this …
multiple sclerosis has led to attempts to modify the immune system of patients with this …
[HTML][HTML] Recomendações quanto ao uso de drogas imunomoduladoras na esclerose múltipla: o consenso do BCTRIMS
CP Tilbery, MA Moreira, MF Mendes… - Arquivos de Neuro …, 2000 - SciELO Brasil
SciELO - Brasil - Recomendações quanto ao uso de drogas imunomoduladoras na esclerose
múltipla: o consenso do BCTRIMS Recomendações quanto ao uso de drogas …
múltipla: o consenso do BCTRIMS Recomendações quanto ao uso de drogas …
Recombinant interferon-β-1a: a review of its therapeutic efficacy in relapsing-remitting multiple sclerosis
AJ Wagstaff, KL Goa - Biodrugs, 1998 - Springer
This review focuses on Rebif®, one of 2 available formulations of recombinant interferon-β-
1a, a molecule with the same molecular weight and primary structure as native interferon-β …
1a, a molecule with the same molecular weight and primary structure as native interferon-β …
Motor neurone disease: Basic designs, sample sizes and pitfalls
BR Brooks, M Sanjak, D Belden, A Waclawik - Clinical Trials in Neurology, 2001 - Springer
In the last quarter-century the assault on motor neurone disease (MND)/amyotrophic lateral
sclerosis (ALS) was initiated by single-center small clinical trials with technically complex …
sclerosis (ALS) was initiated by single-center small clinical trials with technically complex …
Management of relapsing-remitting multiple sclerosis: defining the role of subcutaneous recombinant interferon-β-1a (Rebif®)
KA Lyseng-Williamson, GL Plosker - Disease Management and Health …, 2002 - Springer
Multiple sclerosis (MS) is a chronic neurological disease of adults that affects over 1 million
people worldwide. Relapsing-remitting MS, characterized by acute attacks (relapses) …
people worldwide. Relapsing-remitting MS, characterized by acute attacks (relapses) …